Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities

by Emily K. Kleczko, Lynn E. Heasley
Published 2018-02-01

Eicosanoids in Cancer: New Roles in Immunoregulation

by Amber M. Johnson, Emily K. Kleczko, Raphael A. Nemenoff
Published 2020-11-01

Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer

by Emily K Kleczko, Raphael A Nemenoff, Michael William Knitz
Published 2021-03-01

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer

by Emily K. Kleczko, Jeff W. Kwak, Erin L. Schenk, Raphael A. Nemenoff
Published 2019-05-01

An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases.

by Emily K Kleczko, Jihye Kim, Stephen B Keysar, Lydia R Heasley, Justin R Eagles, Matthew Simon, Marianne E Marshall, Katherine R Singleton, Antonio Jimeno, Aik-Choon Tan, Lynn E Heasley
Published 2015-01-01